The most common side effects of Wegovy, and how to think about them

Why GI side effects are so common with Wegovy

Semaglutide slows the rate at which food leaves your stomach. That is one of the mechanisms behind its appetite-reducing effect, but it is also the reason so many of the most common side effects of Wegovy involve the digestive system. Your gut is working differently than it was before, and it takes time to adjust.

In the STEP 1 clinical trial (1,961 adults, 68 weeks, published in the New England Journal of Medicine) nausea affected around 44% of participants on semaglutide, compared with about 16% on placebo. Diarrhoea, vomiting and constipation each affected roughly 30% or fewer. These figures sound significant, but the trial also showed that most events were rated mild or moderate in severity, and that rates dropped substantially after the initial titration period.

A widespread misconception is that experiencing nausea means the medicine is harming you. In most cases it reflects the medicine doing exactly what it is designed to do, and the body catching up. That does not mean you have to tolerate it badly; practical steps like eating smaller portions, avoiding fatty or spicy foods and staying well hydrated make a real difference for many people. If side effects feel unmanageable, your prescriber can discuss the pace of dose increases.

Other effects reported in trials include headache, fatigue, dizziness, burping and injection-site reactions such as mild redness or itching. None of these are reasons to panic, but all are worth noting and mentioning at your next clinical review.

Side effects that need prompt medical attention

The NHS and the MHRA are clear that, while serious side effects are uncommon, they are real and should not be brushed aside. Knowing the warning signs matters.

In January 2026, the MHRA issued a Drug Safety Update highlighting acute pancreatitis as a known but infrequent risk with GLP-1 medicines including semaglutide. The symptom to recognise is severe, persistent stomach pain, particularly pain that spreads towards the back, with or without vomiting. If that happens, stop taking Wegovy and seek urgent medical help. Do not wait to see if it passes.

Gallbladder problems, including gallstones and inflammation, have also been reported. The signs can include pain in the upper right abdomen, nausea and fever. Again: urgent attention rather than watchful waiting.

Dehydration from prolonged vomiting or diarrhoea can put strain on the kidneys, especially if you are also taking medicines that affect kidney function. Drinking enough fluids during a rough patch is not just comfort advice, it is clinically relevant. If you cannot keep fluids down for more than a day, contact a healthcare professional.

Allergic reactions are rare but possible. Swelling of the face, throat or tongue, difficulty breathing and a rapid heartbeat are signs to call 999 immediately. You can find the full list of side effects and their frequencies in the Wegovy Summary of Product Characteristics on the eMC.

Who experiences more side effects, and who experiences fewer

Not everyone's experience looks the same, and that is not random. Several factors shape how someone responds to the titration schedule.

People who titrate slowly (spending longer at each dose before moving to the next) generally report fewer and milder GI effects. This is partly why the prescribing schedule starts at 0.25mg: the first months are about letting your system adjust, not about maximum effect. Rushing the dose ladder tends to produce a rougher experience.

Eating habits also matter. Large meals, high-fat foods and alcohol are all more likely to aggravate nausea when gastric emptying is already slowed. Some people find that their appetite has dropped so sharply that they eat too little, which paradoxically can worsen symptoms through low blood sugar or undereating. Adequate protein, fibre and hydration become more important during treatment, not less.

People with a history of pancreatitis, serious gastrointestinal conditions or gallbladder disease may not be suitable candidates for semaglutide at all. This is one of the reasons a thorough clinical assessment exists, not as a bureaucratic hurdle, but because a prescriber identifying a contraindication before treatment starts is far better than discovering it after. Our Wegovy overview page covers the eligibility picture in more detail, and the clinical team who reviews every consultation at nume brings this kind of medical judgement to each case personally.

Reporting side effects and staying supported

If you experience something unexpected on Wegovy, you have two routes: speak to your prescriber, and report it to the MHRA. Both matter. Your prescriber can adjust your plan, slowing titration, advising on managing a specific symptom, or deciding whether continuing is right for you. The MHRA's Yellow Card scheme collects real-world safety data that shapes ongoing monitoring of medicines after they are licensed. Reporting is straightforward at yellowcard.mhra.gov.uk, and patients can submit reports directly without going through a doctor.

For a broader look at how semaglutide's side effects compare across different populations, the semaglutide common side effects page covers the wider evidence. If you are specifically wondering how often nausea affects people week to week, the nausea frequency guide goes into more depth on that question alone.

At nume, our prescribers discuss side effects as part of the consultation, not as a disclaimer read out at the end, but as a genuine part of working out whether Wegovy is the right fit for you at this point. If you want a clear breakdown of what the common side effects of Wegovy actually are before your first appointment, that page sets out the full picture, and if you are curious about whether most people have side effects from Wegovy at all, we cover that question directly too. Aftercare is available seven days a week if something comes up after treatment starts. If you are thinking about whether to begin, check your eligibility with a free consultation.